argenx SE (LTS:0QW0) Other Long Term Assets : €0 Mil (As of Mar. 2025)

View and export this data going back to 2014. Start your Free Trial

What is argenx SE Other Long Term Assets?

argenx SE's other long-term assets for the quarter that ended in Mar. 2025 was €0 Mil.

argenx SE's quarterly other long-term assets increased from Sep. 2024 (€0 Mil) to Dec. 2024 (€998 Mil) but then stayed the same from Dec. 2024 (€998 Mil) to Mar. 2025 (€0 Mil).

argenx SE's annual other long-term assets increased from Dec. 2022 (€121 Mil) to Dec. 2023 (€205 Mil) and increased from Dec. 2023 (€205 Mil) to Dec. 2024 (€998 Mil).

argenx SE Other Long Term Assets Historical Data

The historical data trend for argenx SE's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Other Long Term Assets Chart

argenx SE Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Long Term Assets

Get a 7-Day Free Trial

30.56

58.95

121.25

205.10

997.74

argenx SE Quarterly Data
	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Other Long Term Assets	Get a 7-Day Free Trial															-	293.06	-	997.74	-

argenx SE Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

argenx SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (LTS:0QW0) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

ARGX:USA ARGXb:UK 1AEA:Germany 1AE:Germany A1RG34:Brazil ARGX:Belgium ARGX:Austria

Address

Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB

Website

https://www.argenx.com

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

argenx SE Headlines

No Headlines